Apimeds Pharmaceuticals Files 2024 10-K Report

Ticker: APUS · Form: 10-K · Filed: Apr 15, 2025 · CIK: 1894525

Apimeds Pharmaceuticals Us, INC. 10-K Filing Summary
FieldDetail
CompanyApimeds Pharmaceuticals Us, INC. (APUS)
Form Type10-K
Filed DateApr 15, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Apimeds Pharma filed its 2024 10-K. Check financials.

AI Summary

Apimeds Pharmaceuticals US, Inc. filed its annual report on Form 10-K for the fiscal year ended December 31, 2024. The company, incorporated in Delaware with its principal executive offices in Hopewell, NJ, operates in the pharmaceutical preparations industry. The filing was made on April 15, 2025, under SEC file number 001-42545.

Why It Matters

This 10-K filing provides a comprehensive overview of Apimeds Pharmaceuticals' financial performance and business operations for the fiscal year 2024, crucial for investors and stakeholders to assess the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a standard annual filing and does not inherently indicate new risks.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Apimeds Pharmaceuticals US, Inc.?

Apimeds Pharmaceuticals US, Inc. operates in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.

When was the 10-K report filed?

The 10-K report was filed on April 15, 2025.

What fiscal year does this 10-K report cover?

This 10-K report covers the fiscal year ended December 31, 2024.

Where are Apimeds Pharmaceuticals US, Inc.'s principal executive offices located?

The principal executive offices of Apimeds Pharmaceuticals US, Inc. are located at 2 East Broad Street, 2nd Floor, Hopewell, NJ 08425.

What is the company's SEC file number?

The company's SEC file number is 001-42545.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on April 15, 2025 regarding Apimeds Pharmaceuticals US, Inc. (APUS).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing